Atai Life Sciences NV agreed to buy full control of smaller UK rival Beckley Psytech Ltd. and raised $30 million in fresh ...

Tris Pharma Inc. can’t be sued by the state of Texas for manipulating test results on medication to treat minors for ...

Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Sanofi will buy the US maker of the world’s only approved treatment for a debilitating rare blood disorder for up to $9.5bn, as it seeks to boost its immunology medicine pipeline.

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

Is this tech company behind CEO's bid for 23andMe genetic data? How Anne Wojcicki's group still could snag 23andMe How Anne ...

US stock futures fell as investors reviewed the latest tariffs news, including China's accusations against the U.S. and ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...

Market update: Defence and gold stocks in demand, FTSE 100 holds firm 09:48 , Graeme Evans Babcock ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...